FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362542247> ?p ?o ?g. }

• W4362542247 endingPage "4992" @default.
• W4362542247 startingPage "4992" @default.
• W4362542247 abstract "Abstract Background: Bromodomain-containing protein 4 (BRD4) has been widely studied as an attractive therapeutic target of prostate cancer (PCa). Currently, a number of BRD4 inhibitors or degraders have been discovered. However, recent studies revealed that SPOP mutant of prostate cancer patients leads to BRD4 stabilization and resulted in JQ1-resistant. Therefore, to reveal the mechanism underlying BRD4 stability may improve the clinical response rate and efficacy of BRD4-targeted therapy in PCa patients. Methods: To evaluate the level of BRD4 during the mitosis phase, we applied a Confocal microscope and WB. In vitro kinase assay and Mass spectrometry were applied to test the phosphorylation of BRD4 by PLK1. A homemade phosphorylation-specific antibody was used to verify p-BRD4 in PCa cells and a tissue micro-array. A PDX-tumor model was used to evaluate the combination efficacy of Taxol to overcome JQ1-resistant. Result: We found that the level of BRD4 obviously decreased during the mitosis phase of PCa cells. Upon releasing from M-phase arrest, BRD4 level increased along with PLK1 decreasing in PCa cell lines, suggesting PLK1 might be involved in the degradation of BRD4 in the M-phase. We found that PBD domain of PLK1 was responsible for interacting with CTD of BRD4. Enforced overexpression of PLK1 promoted BRD4 dramatically reduced. Reversely, tet-induced depletion or inhibition of PLK1 led to BRD4 stabilization. Furthermore, applying gain or loss of function assay, we found that PLK1 directly phosphorylated BRD4 and triggered its phosphorylation-dependent degradation in M-phase, which was confirmed in clinical samples that high level of PLK1 was negatively correlated with BRD4. Accordingly, we found that overexpression of PLK1 lowered the stabilized BRD4 caused by SPOP mutant in PCa cells and consequently made cells sensitive to JQ1. Intriguingly, upon treated with Taxol, a commonly used medicine for PCa patients, PLK1 level was dramatically elevated as well as p-BRD4 status but total BRD4 downregulated in PCa cells. Moreover, sequential treatment of Taxol and JQ1 resulted in significant inhibition of proliferation, colony formation, and PDX tumor carrying SPOP mutant, indicating application of Taxol overcame JQ-1 resistant. Conclusion: Collectively, our results suggested that PLK1 phosphorylates BRD4 and consequently triggers its phosphorylation-dependent degradation in PCa cells. Sequential treatment of Taxol and JQ1 overcomes SPOP mutant-related BETi-resistant in prostate cancer. Citation Format: Yanquan Zhang, Ka Will Fong, Fengyi Mao, Ruixin Wang, Yifan Kong, Chaohao Li, Jinghui Liu, Zhiguo Li, Derek B. Allison, Dana Napier, Daheng Li, Jinpeng Liu, Chi Wang, Yeqing Zhang, Guangbing Li, Xiaoqi Liu. Taxol-elevated PLK1 overcomes BETi-resistant in prostate cancer via triggering phosphorylation-dependent degradation of BRD4. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4992." @default.
• W4362542247 created "2023-04-06" @default.
• W4362542247 creator A5009997945 @default.
• W4362542247 creator A5012453035 @default.
• W4362542247 creator A5015978857 @default.
• W4362542247 creator A5021562291 @default.
• W4362542247 creator A5025866858 @default.
• W4362542247 creator A5042097384 @default.
• W4362542247 creator A5046352646 @default.
• W4362542247 creator A5051722330 @default.
• W4362542247 creator A5054298214 @default.
• W4362542247 creator A5069121438 @default.
• W4362542247 creator A5071282511 @default.
• W4362542247 creator A5073746929 @default.
• W4362542247 creator A5075131710 @default.
• W4362542247 creator A5084750885 @default.
• W4362542247 creator A5085066323 @default.
• W4362542247 creator A5087099571 @default.
• W4362542247 date "2023-04-04" @default.
• W4362542247 modified "2023-09-25" @default.
• W4362542247 title "Abstract 4992: Taxol-elevated PLK1 overcomes BETi-resistant in prostate cancer via triggering phosphorylation-dependent degradation of BRD4" @default.
• W4362542247 doi "https://doi.org/10.1158/1538-7445.am2023-4992" @default.
• W4362542247 hasPublicationYear "2023" @default.
• W4362542247 type Work @default.
• W4362542247 citedByCount "0" @default.
• W4362542247 crossrefType "journal-article" @default.
• W4362542247 hasAuthorship W4362542247A5009997945 @default.
• W4362542247 hasAuthorship W4362542247A5012453035 @default.
• W4362542247 hasAuthorship W4362542247A5015978857 @default.
• W4362542247 hasAuthorship W4362542247A5021562291 @default.
• W4362542247 hasAuthorship W4362542247A5025866858 @default.
• W4362542247 hasAuthorship W4362542247A5042097384 @default.
• W4362542247 hasAuthorship W4362542247A5046352646 @default.
• W4362542247 hasAuthorship W4362542247A5051722330 @default.
• W4362542247 hasAuthorship W4362542247A5054298214 @default.
• W4362542247 hasAuthorship W4362542247A5069121438 @default.
• W4362542247 hasAuthorship W4362542247A5071282511 @default.
• W4362542247 hasAuthorship W4362542247A5073746929 @default.
• W4362542247 hasAuthorship W4362542247A5075131710 @default.
• W4362542247 hasAuthorship W4362542247A5084750885 @default.
• W4362542247 hasAuthorship W4362542247A5085066323 @default.
• W4362542247 hasAuthorship W4362542247A5087099571 @default.
• W4362542247 hasConcept C11960822 @default.
• W4362542247 hasConcept C146276462 @default.
• W4362542247 hasConcept C1491633281 @default.
• W4362542247 hasConcept C184235292 @default.
• W4362542247 hasConcept C185592680 @default.
• W4362542247 hasConcept C2779634854 @default.
• W4362542247 hasConcept C29537977 @default.
• W4362542247 hasConcept C502942594 @default.
• W4362542247 hasConcept C552990157 @default.
• W4362542247 hasConcept C55493867 @default.
• W4362542247 hasConcept C64927066 @default.
• W4362542247 hasConcept C74401373 @default.
• W4362542247 hasConcept C86803240 @default.
• W4362542247 hasConcept C93304396 @default.
• W4362542247 hasConcept C95444343 @default.
• W4362542247 hasConceptScore W4362542247C11960822 @default.
• W4362542247 hasConceptScore W4362542247C146276462 @default.
• W4362542247 hasConceptScore W4362542247C1491633281 @default.
• W4362542247 hasConceptScore W4362542247C184235292 @default.
• W4362542247 hasConceptScore W4362542247C185592680 @default.
• W4362542247 hasConceptScore W4362542247C2779634854 @default.
• W4362542247 hasConceptScore W4362542247C29537977 @default.
• W4362542247 hasConceptScore W4362542247C502942594 @default.
• W4362542247 hasConceptScore W4362542247C552990157 @default.
• W4362542247 hasConceptScore W4362542247C55493867 @default.
• W4362542247 hasConceptScore W4362542247C64927066 @default.
• W4362542247 hasConceptScore W4362542247C74401373 @default.
• W4362542247 hasConceptScore W4362542247C86803240 @default.
• W4362542247 hasConceptScore W4362542247C93304396 @default.
• W4362542247 hasConceptScore W4362542247C95444343 @default.
• W4362542247 hasIssue "7_Supplement" @default.
• W4362542247 hasLocation W43625422471 @default.
• W4362542247 hasOpenAccess W4362542247 @default.
• W4362542247 hasPrimaryLocation W43625422471 @default.
• W4362542247 hasRelatedWork W1535915839 @default.
• W4362542247 hasRelatedWork W1978377027 @default.
• W4362542247 hasRelatedWork W1986281342 @default.
• W4362542247 hasRelatedWork W2001265502 @default.
• W4362542247 hasRelatedWork W2019807707 @default.
• W4362542247 hasRelatedWork W2046009879 @default.
• W4362542247 hasRelatedWork W2051420187 @default.
• W4362542247 hasRelatedWork W2060503228 @default.
• W4362542247 hasRelatedWork W2067951423 @default.
• W4362542247 hasRelatedWork W4225421620 @default.
• W4362542247 hasVolume "83" @default.
• W4362542247 isParatext "false" @default.
• W4362542247 isRetracted "false" @default.
• W4362542247 workType "article" @default.